Zevra Therapeutics, Inc.
ZVRA
NASDAQ·Healthcare·Biotechnology·Mkt cap $733.0M
$12.40
▼ -1.12%
P/E
13.05
Mkt Cap
$733.0M
52-Wk Range
$7.16–$15.04
52-Week Range
$7.16 - $15.04
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 48.9% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Proprietary Ligand Activated Therapy platform enabling superior prodrug formulations
- FDA-approved commercial products generating near-term revenue
- Focused pipeline addressing high-need rare disease indications with limited treatment options
- Differentiated pharmacokinetic profiles reducing abuse potential and side effects
- Strategic partnerships enhancing development and commercialization capabilities
Bear Case
1 risk
- Average volatility.
Growth
Moderate growth ahead
Strong revenue growth (351% YoY)
Value
Trading at 0.5x Biotech & Therapeutics peers — a discount despite the growth profile.
Momentum
Stable
+2.6% over 3m
Quality
Excellent
High-growth business (119% revenue growth, 95% gross margin). Profitable with strong growth momentum.
Dividend
None
No dividend
Smart-money signal
Who's buying ZVRA right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 4, 2026
AUG 5, 2026
Reported EPS of $0.14 vs $0.11 consensus (+27.3% surprise). Revenue of $39.7M vs $33.9M expected (+17.1%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+27.3%
Revenue trend · last 8Q
—
-9%
+496%
+482%
+605%
+183%
+78%
+53%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$3.7M
$12.0M
$20.4M
$25.9M
$26.1M
$34.1M
$36.2M
$39.7M
Margins · last 8Q
Gross
96.2%
Operating
42.3%
Profit
22.1%
Wall Street consensus
6 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Citi · Aug 6, 2026
vs Industry
How ZVRA stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related